Transcranial brain stimulation to study memory processing and synaptic plasticity during sleep

ROBMIT – ROBotic MIrrored Therapy after stroke

BOSS-STROKE – Brain-oscillation-synchronized stimulation to enhance motor recovery in early subacute stroke: A randomized controlled double-blind threearm parallel-group exploratory trial comparing personalized, non-personalized and sham repetitive transcranial magnetic stimulation

ConnectToBrain – Connecting to the Networks of the Human Brain

FASTEST – rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time

FIND AF

ESCAPE MeVO

Andexanet alfa: non- interventional stud in Stroke Units in Germany

ODEA TIA

SMARTCOIL – Personalisierte therapeutische Hirnstimulation

ENSEMBLE – AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATETHE EFFECTIVENESS AND SAFETY OFOCRELIZUMAB IN PATIENTS WITH EARLY STAGERELAPSING REMITTING MULTIPLE SCLEROSIS

Andexanet alpha. non interventional study in Stoke Units in Germany (DE)

ELAN

ESCAPE-NEXT

„Multicenter, randomized, placebo-controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute noncardioembolic ischemic stroke“

ATTICUS Amendment C – Apixaban for treatment of embolic stroke of undetermined source

Prestige AF

OCEANIC Stroke

Annexai

PRediction of Acute coronary syndrome in acute Ischemic StrokE (PRAISE)

REHALITY – Verbundprojekt: Closed-loop Softwaresystem zur Neurorehabilitation nach Schlaganfall durch personalisiertes EEG/EMG-Hirnzustand-gesteuertes Virtual Reality-Therapieparadigma

Therapie des invasiven Glioblastoms mittels intranasaler Applikation von Shuttle-Zellen als Transporter für onkolytische Adenoviren"

Revision

GLIOPT – Gliompatienten in der ambulanten Versorgung - Optimierung der psycho-sozialen Versorgung bei neuroonkologischen Patienten

Apices

Axiomatic - BMS – A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Response-Adaptive Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)

PRAISE

CERETEP – Electroencephalographical signatures in cerebral cortex evoked by cerebellar transcranial magnetic stimulation

Registry of Idarucizumab for Patients with IntraCranial Hemmorrhage (RIC-ICH)

SANO – Strukturierte ambulante Nachsorge nach Schlaganfall (SANO)

Closed-loop TMS triggered by real-time cortical excitability states for neural rehabilitation of patients with disorders of consciousness

TIGER – The use of TTFields for newly diagnosed GBM patients in Germany in routine clinical care - TIGER STudy

ATTICUS – Apixaban for treatment of embolic stroke of undetermined source

ATTICUS Amendment B – Apixaban for treatment of embolic stroke of undetermined source

PROOF

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Kooperationsvertrag zwischen UKT und m&i Klinikgruppe Enzensberg

The sensorimotor µ-rhythm as cholinergically controlled pulsed inhibition

Annexa 4

64. Jahrestagung der Deutschen Gesellschaft für Klinische Neurophysiologie und Funktionelle Bildgebung Baden-Baden 26.-28.03.2020

Prevention of complications to improve outcome in elderly patients with acute stroke.

Bayer feasibility BAY 2433334 / 19776

STREAM

Edoxaban

DS1040-A-U103 – DS1040b in subjects with acute ischemic stroke

PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. A randomised, open, phase III, clinical trial with blinded outcome assessment

Atticus – Apixaban for treatment of embolic Stroke